

Corrigendum to: Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies

Maurizio Taramasso, Christelle Calen, Andrea Guidotti, Shingo Kuwata, Hector Rodriguez Cetina Biefer,
Fabian Nietlispach, Michel Zuber and Francesco Maisano

Heart Valve Clinic, University Hospital of Zurich, University of Zurich, Zurich, Switzerland

Citation: *Interventional Cardiology Review* 2020;15:e12. **DOI:** <https://doi.org/10.15420/icr.2020.22>

Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

In the article by Taramasso et al. entitled Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies (*Interventional Cardiology Review* 2017;12(1):51–5. <https://doi.org/10.15420/icr.2017:3:2>), the following correction should be made.

The authors' conflicts of interest were omitted at the time of publication. They should read as follows:

Maurizio Taramasso is a consultant for Abbott Vascular, Boston Scientific and 4tech; received personal fees from Edwards Lifesciences, Mitraltech, CoreMedic and Swissvortex; and is a shareholder of 4Tech.

Fabian Nietlispach serves a consultant for Edwards Lifesciences, Abbott, Medtronic and St Jude Medical.

Michel Zuber is a consultant for Abbott and Edwards Lifesciences.

Francesco Maisano discloses grant and/or research support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT and Terumo; consulting fees and honoraria from Abbott, Medtronic, Edwards Lifesciences, Swissvortex, Perifect, Xeltis, Transseptal Solutions, Cardiovalve (Mitraltech) and Magenta; royalty income/IP rights from Edwards Lifesciences; and is a shareholder of Cardiogard, Magenta, SwissVortex, Transseptalsolutions, Occlufit, 4Tech and Perifect.

All other authors have no conflicts of interest to declare.

The authors apologise for this error. ■